Schedule 1 Cannabis Lawsuit and DEA Rescheduling Update: March 2026 Status

As of March 18, 2026, the federal government is locked in a high-stakes legal battle over the future of the Controlled Substances Act (CSA). Following an unprecedented executive order signed in late 2025, the Trump administration has aggressively moved to reclassify marijuana from Schedule I to Schedule III. However, this transition has sparked a “war of petitions” and multiple lawsuits, with groups like Doctors for Drug Policy Reform (D4DPR) and Smart Approaches to Marijuana (SAM) challenging the Drug Enforcement Administration (DEA) from opposite ends of the ideological spectrum.

The D4DPR Lawsuit: Challenging DEA Bias

One of the most significant legal hurdles currently facing the rescheduling process is the lawsuit filed by Doctors for Drug Policy Reform in the U.S. Court of Appeals for the DC Circuit. In a 56-page brief submitted in February 2026, the group of over 400 physicians accused the DEA of conducting an “opaque and biased” selection process for its administrative hearings. The lawsuit alleges that the DEA arbitrarily rejected 138 out of 163 applicants who wished to testify in favor of rescheduling, while prioritizing participants who remain steadfast in their support of Schedule I prohibition.

As of March 2026, the D4DPR is seeking a court order to force the DEA to redo its participant selection process. This litigation has effectively placed a stay on the formal Administrative Law Judge (ALJ) hearings, which were originally slated to conclude by mid-2025. Legal analysts suggest that if the DC Circuit rules in favor of the doctors, the final publication of the Schedule III rule could be delayed until late 2027 or even 2028.

The 2026 Rescheduling Executive Order

Despite the procedural delays in the courts, the executive branch has signaled its intent to bypass traditional “bureaucratic stalling.” In January 2026, the administration directed the Attorney General to “take all necessary steps” to finalize the reclassification. The administration’s primary stated goal for moving cannabis to Schedule III is to facilitate expanded medical research and to provide a federally recognized alternative to the opioid crisis.

However, the DEA’s internal leadership remains a point of friction. The recent appointment of a new, anti-cannabis DEA Administrator in early 2026 has created what former lawmakers describe as a “widening chasm” within the GOP. While the libertarian wing of the party supports the economic benefits of rescheduling, the traditionalist wing continues to view any deviation from Schedule I as a threat to national drug control policy.

Taxation and the “280E” Resolution

For the cannabis industry, the “Schedule 1 Lawsuit” is less about criminal justice and more about survival against Internal Revenue Code Section 280E. Under Schedule I, state-legal cannabis businesses are prohibited from claiming standard business deductions, leading to effective tax rates often exceeding 70%. In March 2026, several “protective refund” lawsuits are moving through federal tax courts, with operators arguing that the government’s own admission that cannabis has “accepted medical use” should trigger an immediate end to 280E, even before the final rule is published.

The IRS issued guidance in June 2024 stating that 280E remains in effect until the “final rule” is signed. However, the 2026 litigation argues that the Department of Health and Human Services (HHS) scientific finding in 2023 was the actual legal “trigger” that rendered Schedule I status—and its associated tax penalties—unconstitutional under the Due Process Clause.

Regulatory Compliance and Future-Proofing

The transition from a Schedule I “prohibition” model to a Schedule III “regulated” model requires a total overhaul of corporate compliance. In complex industries like commercial development, integrated design and construction models are used to manage multi-layered regulatory requirements and ensure transparency. Similarly, as the cannabis sector prepares for FDA oversight, staying informed on employment law updates for 2026 is essential for businesses that must now align their workplace drug policies with a federally recognized medical framework.

March 2026: Key Deadlines and What to Expect

While the rescheduling process is “hazy,” the following milestones are critical for the remainder of 2026:

• ALJ Hearing Restart: If the DC Circuit clears the D4DPR appeal by May 2026, hearings could resume by late summer.
• The 2026 Farm Bill: Watch for language in the final 2026 Farm Bill regarding hemp-derived THC, as lawmakers look to close the “loophole” that has allowed intoxicating hemp products to compete with licensed cannabis.
• Banking Reform: Rescheduling is expected to reignite the SAFER Banking Act, which has remained stalled in Congress pending the final DEA classification.